Inogen Inc (INGN) Expected to Post Quarterly Sales of $91.98 Million

Analysts expect Inogen Inc (NASDAQ:INGN) to announce sales of $91.98 million for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Inogen’s earnings. The lowest sales estimate is $86.79 million and the highest is $96.49 million. Inogen reported sales of $79.05 million during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The company is scheduled to report its next earnings report on Monday, April 29th.

According to Zacks, analysts expect that Inogen will report full-year sales of $434.12 million for the current fiscal year, with estimates ranging from $432.08 million to $435.15 million. For the next fiscal year, analysts anticipate that the business will post sales of $517.59 million, with estimates ranging from $503.60 million to $528.22 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Inogen.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 26th. The medical technology company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.19. Inogen had a net margin of 14.48% and a return on equity of 18.60%. The firm had revenue of $86.50 million for the quarter, compared to the consensus estimate of $82.06 million. During the same period in the prior year, the firm earned ($0.03) EPS. The firm’s revenue for the quarter was up 35.6% on a year-over-year basis.



Several equities analysts have recently issued reports on the stock. BidaskClub downgraded shares of Inogen from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. ValuEngine downgraded Inogen from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. JPMorgan Chase & Co. reduced their price target on Inogen to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 27th. Piper Jaffray Companies reduced their price target on Inogen from $290.00 to $185.00 and set an “overweight” rating on the stock in a report on Wednesday, February 27th. Finally, Needham & Company LLC restated a “strong-buy” rating and set a $191.00 price target (down previously from $280.00) on shares of Inogen in a report on Wednesday, February 27th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $189.00.

Shares of INGN traded down $2.84 during midday trading on Wednesday, hitting $93.27. 423,800 shares of the stock traded hands, compared to its average volume of 621,907. Inogen has a 1-year low of $91.90 and a 1-year high of $287.79. The company has a market cap of $2.10 billion, a price-to-earnings ratio of 40.55, a price-to-earnings-growth ratio of 3.16 and a beta of 1.51.

In other news, Director Raymond Huggenberger sold 8,500 shares of the business’s stock in a transaction that occurred on Tuesday, January 15th. The stock was sold at an average price of $136.81, for a total value of $1,162,885.00. Following the sale, the director now directly owns 11,297 shares of the company’s stock, valued at approximately $1,545,542.57. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 5.29% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Bowling Portfolio Management LLC bought a new position in Inogen in the 4th quarter valued at approximately $345,000. Sapphire Star Partners LP lifted its position in Inogen by 1.9% in the 4th quarter. Sapphire Star Partners LP now owns 7,437 shares of the medical technology company’s stock valued at $924,000 after acquiring an additional 136 shares in the last quarter. Malaga Cove Capital LLC bought a new position in Inogen in the 4th quarter valued at approximately $576,000. Mackenzie Financial Corp bought a new position in Inogen in the 4th quarter valued at approximately $2,506,000. Finally, Advisors Asset Management Inc. lifted its position in Inogen by 2,634.0% in the 3rd quarter. Advisors Asset Management Inc. now owns 1,285 shares of the medical technology company’s stock valued at $314,000 after acquiring an additional 1,238 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: Do back-end load funds outperform no-load funds?

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.